Log in to save to my catalogue

Liver and pancreatic-targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated s...

Liver and pancreatic-targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated s...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_5c697ee738e34e89bcba2d1629c34f97

Liver and pancreatic-targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated steatohepatitis

About this item

Full title

Liver and pancreatic-targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated steatohepatitis

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2024-05, Vol.15 (1), p.4528-13, Article 4528

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Metabolic dysfunction-associated steatohepatitis (MASH) is the most prevalent cause of liver disease worldwide, with a single approved therapeutic. Previous research has shown that interleukin-22 (IL-22) can suppress β-cell stress, reduce local islet inflammation, restore appropriate insulin production, reverse hyperglycemia, and ameliorate insulin...

Alternative Titles

Full title

Liver and pancreatic-targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated steatohepatitis

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_5c697ee738e34e89bcba2d1629c34f97

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_5c697ee738e34e89bcba2d1629c34f97

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-024-48317-x

How to access this item